Azacitidine Accord

azacitidine

Table of contents

Opinion

On 12 December 2019, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Azacitidine Accord, intended for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia. The applicant for this medicinal product is Accord Healthcare S.L.U.

Azacitidine Accord will be available as a 25 mg/ml powder for suspension for injection. The active substance of Azacitidine Accord is azacitidine, a pyrimidine analogue (ATC code: L01BC07) which exerts its antineoplastic effects by multiple mechanisms, including cytotoxicity on cells in the bone marrow and hypomethylation of DNA.

Azacitidine Accord is a generic of Vidaza, which has been authorised in the EU since 17 December 2008. Studies have demonstrated the satisfactory quality of Azacitidine Accord. Since Azacitidine Accord is administered intravenously and is 100% bioavailable, a bioequivalence study versus the reference product Vidaza was not required. 

The full indication is:

"Azacitidine Accord is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:

  • Intermediate 2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),
  • chronic myelomonocytic leukaemia (CMML) with 10 29 % marrow blasts without myeloproliferative disorder,
  • acute myeloid leukaemia (AML) with 20 30 % blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification,
  • AML with >30% marrow blasts according to the WHO classification."

It is proposed that Azacitidine Accord be prescribed by physicians experienced in the use of chemotherapeutic agents.

Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published in the European public assessment report (EPAR) and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

Key facts

Name
Azacitidine Accord
Agency product number
EMEA/H/C/005147
International non-proprietary name (INN) or common name
  • azacitidine
Active substance
  • azacitidine
Therapeutic area
Myelodysplastic Syndromes
Leukemia, Myelomonocytic, Chronic
Leukemia, Myeloid, Acute
Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Date opinion adopted
12/12/2019
Company name
Accord Healthcare S.L.U.
Status
Positive
Application type
Initial authorisation

How useful was this page?

Add your rating